Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | El-Moukhtari, S.H. (Souhaila H.) | - |
dc.creator | Rodriguez-Nogales, C. (Carlos) | - |
dc.creator | Blanco-Prieto, M.J. (María José) | - |
dc.date.accessioned | 2022-06-28T09:32:28Z | - |
dc.date.available | 2022-06-28T09:32:28Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | El-Moukhtari, S.H. (Souhaila H.); Rodriguez-Nogales, C. (Carlos); Blanco-Prieto, M.J. (María José). "Oral lipid nanomedicines: Current status and future perspectives in cancer treatment". Advanced Drug Delivery Reviews. (173), 2021, 238 - 251 | es_ES |
dc.identifier.issn | 0169-409X | - |
dc.identifier.uri | https://hdl.handle.net/10171/63700 | - |
dc.description.abstract | Oral anticancer drugs have earned a seat at the table, as the need for homecare treatment in oncology has increased. Interest in this field is growing as a result of their proven efficacy, lower costs and positive patient uptake. However, the gastrointestinal barrier is still the main obstacle to surmount in chemother- apeutic oral delivery. Anticancer nanomedicines have been proposed to solve this quandary. Among these, lipid nanoparticles are described to be efficiently absorbed while protecting drugs from early degradation in hostile environments. Their intestinal lymphatic tropism or mucoadhesive/penetrative properties give them unique characteristics for oral administration. Considering that chronic cancer cases are increasing over time, it is important to be able to provide treatments with low toxicity and low prices. The challenges, opportunities and therapeutic perspectives of lipid nanoparticles in this area will be dis- cussed in this review, taking into consideration the pre-clinical and clinical progress made in the last decade. | es_ES |
dc.description.sponsorship | This work was supported by grants from the Children with Neuroblastoma Association (NEN, Nico contra el cancer). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Oral delivery | es_ES |
dc.subject | Nanoparticles | es_ES |
dc.subject | Chemotherapy | es_ES |
dc.subject | Cancer | es_ES |
dc.subject | Solid lipid nanoparticle | es_ES |
dc.subject | Lymphatic system | es_ES |
dc.subject | Gastrointestinal barrier | es_ES |
dc.title | Oral lipid nanomedicines: Current status and future perspectives in cancer treatment | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an open access article under the CC BY-NC-ND license | es_ES |
dc.identifier.doi | 10.1016/j.addr.2021.03.004 | - |
dadun.citation.endingPage | 251 | es_ES |
dadun.citation.number | 173 | es_ES |
dadun.citation.publicationName | Advanced Drug Delivery Reviews | es_ES |
dadun.citation.startingPage | 238 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.